Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 May;33(5):657-62.
doi: 10.1128/AAC.33.5.657.

In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages

Affiliations

In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages

N Ramasesh et al. Antimicrob Agents Chemother. 1989 May.

Abstract

Mycobacterium leprae synthesizes large quantities of a specific phthiocerol-containing phenolic glycolipid in vivo. We have shown earlier that viable M. leprae readily incorporates radiolabeled palmitic acid into phenolic glycolipid I when residing in cultured macrophages in vitro and that this process is inhibited by the antileprosy drug rifampin. In the present paper we report that application of this observation to the rapid evaluation of over 25 antimicrobial agents for potential antileprosy activity in vitro. All the known antileprosy drugs rifampin, dapsone, clofazimine, and ethionamide inhibited phenolic glycolipid I synthesis. Rifabutin, a spiropiperidyl derivative of rifamycin, also reported to be active in the mouse model, was very effective. Interestingly, the macrolides erythromycin, clarithromycin, and roxithromycin were also found to be active in this system, while D-cycloserine and other cell wall synthesis inhibitors showed no effect. Many of the compounds found to be active in this system have been reported to be effective in vivo in mice. This correlation lends support to the feasibility of using phenolic glycolipid I synthesis for the rapid evaluation of new drugs against leprosy.

PubMed Disclaimer

References

    1. Infect Immun. 1987 May;55(5):1203-6 - PubMed
    1. Int J Lepr Other Mycobact Dis. 1987 Mar;55(1):78-82 - PubMed
    1. J Infect Dis. 1987 Jul;156(1):236-9 - PubMed
    1. Lepr Rev. 1987 Dec;58(4):407-11 - PubMed
    1. J Clin Microbiol. 1988 Jan;26(1):18-21 - PubMed

Publication types